Embecta

Embecta R&D per Employee

The R&D Spending per Employee of Embecta (EMBC) as of Nov 11, 2026 is 11,621.62 USD. In the previous year, R&D Spending per Employee was 42,594.59 USD — a change of -72.72% (lower).

R&D per Employee

11,621.62USD

YoY

-72.72%

Last updated:

R&D Spending per Employee of Embecta is 2025 11,621.62 USD. R&D Spending per Employee of Embecta was 2024 42,594.59 USD. It decreases by -72.72% lower compared to the previous year.

The Embecta R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
33,513.51 USD
Jan 1, 2020
32,972.97 USD
Jan 1, 2021
34,054.05 USD
Jan 1, 2022
35,135.14 USD
Jan 1, 2023
46,054.05 USD
Jan 1, 2024
42,594.59 USD
Jan 1, 2025
11,621.62 USD
The Embecta R&D per Employee history
YEARR&D per EmployeeYoY
11,621.62USD-72.72%
42,594.59USD-7.51%
46,054.05USD+31.08%
35,135.14USD+3.17%
34,054.05USD+3.28%
32,972.97USD-1.61%
33,513.51USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

R&D Spending per Employee of Embecta is 11,621.62 USD in 2025.

R&D Spending per Employee of Embecta changed from 42,594.59 USD to 11,621.62 USD, representing a -72.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Embecta since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Embecta

All Key Metrics — Embecta